ZYNERBA PHARMACEUTICALS INC's ticker is ZYNE and the CUSIP is 98986X109. A total of 60 filers reported holding ZYNERBA PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.41 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $445 | +290.4% | 350 | 0.0% | 0.00% | – |
| Q2 2023 | $114 | -24.5% | 350 | 0.0% | 0.00% | – |
| Q1 2023 | $151 | -18.8% | 350 | 0.0% | 0.00% | – |
| Q4 2022 | $186 | – | 350 | 0.0% | 0.00% | – |
| Q3 2022 | $0 | – | 350 | 0.0% | 0.00% | – |
| Q2 2022 | $0 | -100.0% | 350 | 0.0% | 0.00% | – |
| Q1 2022 | $1,000 | 0.0% | 350 | 0.0% | 0.00% | – |
| Q4 2021 | $1,000 | 0.0% | 350 | 0.0% | 0.00% | – |
| Q3 2021 | $1,000 | -50.0% | 350 | 0.0% | 0.00% | – |
| Q2 2021 | $2,000 | -99.9% | 350 | 0.0% | 0.00% | – |
| Q1 2021 | $1,628,000 | +162700.0% | 350 | 0.0% | 0.00% | – |
| Q4 2020 | $1,000 | 0.0% | 350 | 0.0% | 0.00% | – |
| Q3 2020 | $1,000 | 0.0% | 350 | 0.0% | 0.00% | – |
| Q2 2020 | $1,000 | 0.0% | 350 | 0.0% | 0.00% | – |
| Q1 2020 | $1,000 | -50.0% | 350 | 0.0% | 0.00% | – |
| Q4 2019 | $2,000 | -33.3% | 350 | 0.0% | 0.00% | -100.0% |
| Q3 2019 | $3,000 | -40.0% | 350 | 0.0% | 0.00% | -50.0% |
| Q2 2019 | $5,000 | +150.0% | 350 | 0.0% | 0.00% | +100.0% |
| Q1 2019 | $2,000 | – | 350 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 507,191 | $5,107,000 | 0.50% |
| Cormorant Asset Management, LP | 356,600 | $3,591,000 | 0.43% |
| Perceptive Advisors | 558,446 | $5,623,000 | 0.42% |
| NEXTHERA CAPITAL LP | 15,000 | $151,000 | 0.21% |
| EMERALD ADVISERS, LLC | 237,070 | $2,387,000 | 0.11% |
| AUXIER ASSET MANAGEMENT | 17,857 | $180,000 | 0.04% |
| FEDERATED HERMES, INC. | 450,000 | $4,532,000 | 0.01% |
| Nationwide Fund Advisors | 49,473 | $498,000 | 0.00% |
| Catalyst Capital Advisors LLC | 348 | $4,000 | 0.00% |
| DEUTSCHE BANK AG\ | 859 | $8,000 | 0.00% |